Advertisement

Table of Contents

What We're Reading

Masters of Immunology

Cancer Immunology Miniatures

Priority Brief

  • Priority Brief
    Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
    Margaretha G.M. Roemer, Ranjana H. Advani, Robert A. Redd, Geraldine S. Pinkus, Yasodha Natkunam, Azra H. Ligon, Courtney F. Connelly, Christine J. Pak, Christopher D. Carey, Sarah E. Daadi, Bjoern Chapuy, Daphne de Jong, Richard T. Hoppe, Donna S. Neuberg, Margaret A. Shipp and Scott J. Rodig
    Cancer Immunol Res November 1 2016 4 (11) 910-916; DOI:10.1158/2326-6066.CIR-16-0201

    Analysis of Hodgkin lymphomas revealed frequent reduction/loss of antigen-presentation proteins and 9p24.1/PD-L1/PD-L2 alterations. These immune evasion mechanisms had independent prognostic value after frontline therapy and prompt speculation regarding alternative mechanisms of action of PD-1 blockade.

Research Articles

  • Research Articles
    Restoring Retinoic Acid Attenuates Intestinal Inflammation and Tumorigenesis in APCMin/+ Mice
    Hweixian Leong Penny, Tyler R. Prestwood, Nupur Bhattacharya, Fionna Sun, Justin A. Kenkel, Matthew G. Davidson, Lei Shen, Luis A. Zuniga, E. Scott Seeley, Reetesh Pai, Okmi Choi, Lorna Tolentino, Jinshan Wang, Joseph L. Napoli and Edgar G. Engleman
    Cancer Immunol Res November 1 2016 4 (11) 917-926; DOI:10.1158/2326-6066.CIR-15-0038

    Intestinal adenomas are driven by inflammation in familial adenomatous polyposis (FAP) and its APCMin/+ mouse model. FAP patients have reduced intestinal retinoic acid; restoring it in mice ameliorated inflammation and reduced tumor burden, suggesting therapeutic approaches for FAP.

  • Research Articles
    MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer
    Ruoxu Dou, Reiko Nishihara, Yin Cao, Tsuyoshi Hamada, Kosuke Mima, Atsuhiro Masuda, Yohei Masugi, Yan Shi, Mancang Gu, Wanwan Li, Annacarolina da Silva, Katsuhiko Nosho, Xuehong Zhang, Jeffrey A. Meyerhardt, Edward L. Giovannucci, Andrew T. Chan, Charles S. Fuchs, Zhi Rong Qian and Shuji Ogino
    Cancer Immunol Res November 1 2016 4 (11) 927-935; DOI:10.1158/2326-6066.CIR-16-0112

    The population-based data presented in this study support a possible role for microRNA let-7a in the suppression of antitumor immunity in colorectal cancer patients. This may have implications for expanding the benefit of immunotherapy through targeting microRNAs.

  • Research Articles
    Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
    Elliott J. Brea, Claire Y. Oh, Eusebio Manchado, Sadna Budhu, Ron S. Gejman, George Mo, Patrizia Mondello, James E. Han, Casey A. Jarvis, David Ulmert, Qing Xiang, Aaron Y. Chang, Ralph J. Garippa, Taha Merghoub, Jedd D. Wolchok, Neal Rosen, Scott W. Lowe and David A. Scheinberg
    Cancer Immunol Res November 1 2016 4 (11) 936-947; DOI:10.1158/2326-6066.CIR-16-0177

    Kinome screens revealed EGFR and MEK as key to reduced MHCI expression on many tumors. FDA-approved inhibitors of these kinases increased surface MHC-I, providing a rationale for clinically testing similar kinase inhibitors with immunotherapies dependent on MHC-I.

  • Research Articles
    Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer
    Xiao X. Wei, Stephen Chan, Serena Kwek, Jera Lewis, Vinh Dao, Li Zhang, Matthew R. Cooperberg, Charles J. Ryan, Amy M. Lin, Terence W. Friedlander, Brian Rini, Christopher Kane, Jeffry P. Simko, Peter R. Carroll, Eric J. Small and Lawrence Fong
    Cancer Immunol Res November 1 2016 4 (11) 948-958; DOI:10.1158/2326-6066.CIR-16-0042

    GM-CSF is a component of many combination immunotherapeutic strategies. This phase I clinical study investigated GM-CSF effects on circulating and intratumoral immune cells, and found that infiltration of antigen-presenting cells was unaffected, but intratumoral CD8+ T cells increased.

  • Research Articles
    Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
    Douglas B. Johnson, Garrett M. Frampton, Matthew J. Rioth, Erik Yusko, Yaomin Xu, Xingyi Guo, Riley C. Ennis, David Fabrizio, Zachary R. Chalmers, Joel Greenbowe, Siraj M. Ali, Sohail Balasubramanian, James X. Sun, Yuting He, Dennie T. Frederick, Igor Puzanov, Justin M. Balko, Justin M. Cates, Jeffrey S. Ross, Catherine Sanders, Harlan Robins, Yu Shyr, Vincent A. Miller, Philip J. Stephens, Ryan J. Sullivan, Jeffrey A. Sosman and Christine M. Lovly
    Cancer Immunol Res November 1 2016 4 (11) 959-967; DOI:10.1158/2326-6066.CIR-16-0143

    Mutational load, by whole exome sequencing, can correlate with immunotherapy responses. Assessing melanoma mutational load of a fraction of the genome, by hybrid capture-based NGS, provided an accurate surrogate for WES determinations, and predicted response to anti-PD-1.

  • Research Articles
    CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma
    Timothy Chao, Emma E. Furth and Robert H. Vonderheide
    Cancer Immunol Res November 1 2016 4 (11) 968-982; DOI:10.1158/2326-6066.CIR-16-0188

    Tumor-associated neutrophils found in pancreatic tumors were dependent on CXCR2 ligands. The signaling pathways that induce CXCR2 ligand expression were identified, and preventing neutrophil accumulation allowed activated T cells access to the tumor, making CXCR2 a potential therapeutic target.

  • Research Articles
    IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation
    Geok Choo Sim, Chengwen Liu, Ena Wang, Hui Liu, Caitlin Creasy, Zhimin Dai, Willem W. Overwijk, Jason Roszik, Francesco Marincola, Patrick Hwu, Elizabeth Grimm and Laszlo Radvanyi
    Cancer Immunol Res November 1 2016 4 (11) 983-994; DOI:10.1158/2326-6066.CIR-15-0195

    IL2 is not commonly used as immunotherapy due to its induction of regulatory T cells and dangerous cytokine storms. The IL2 variant, F42K, promoted the expansion and activation of antitumor NK cells without inducing highly suppressive Tregs.

Back to top

Jump to

Advertisement